Niagen Bioscience, Inc. (NAGE) Q4 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Niagen Bioscience, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.236 Ladies and gentlemen, thank you for standing by, and welcome to Niagen Bioscience, 00:00:05.236 -- 00:00:09.601 Inc.' 's fourth quarter of 2025 earnings conference call. 00:00:09.601 -- 00:00:12.564 My name is Tiffany, and I will be the conference operator today. 00:00:12.564 -- 00:00:17.669 At this time, all participants are in a listen-only mode, and as a 00:00:17.669 -- 00:00:20.252 reminder, this conference call is being recorded. 00:00:20.252 -- 00:00:25.618 This afternoon, Niagen Bioscience issued a news release announcing 00:00:25.618 -- 00:00:30.601 the company's financial results for the fourth quarter of 2025. 00:00:30.642 -- 00:00:35.988 If you have not reviewed this information, both are available within the investor relations 00:00:35.988 -- 00:00:41.792 section of Niogen Bioscience website at www.niogenbioscience.com. 00:00:44.237 -- 00:00:49.242 I would now like to turn the conference call over to Kendall Knish, Senior Director 00:00:49.242 -- 00:00:53.366 of Publicity and Public Relations. Please go ahead, Ms. 00:00:53.366 -- 00:00:55.366 Knish. 00:00:57.237 -- 00:01:02.346 Thank you, good afternoon, and welcome to Niagen Bioscience, Inc.' 's fourth quarter 00:01:02.346 -- 00:01:08.217 of 2025 results investor call. With us today are Niagen Bioscience's 00:01:08.217 -- 00:01:13.246 Chief Executive Officer, Rob Fried, Chief Financial Officer, Ozan 00:01:13.246 -- 00:01:18.436 Pamir, and Senior Vice President of Scientific and Regulatory Affairs, Dr. 00:01:18.436 -- 00:01:23.637 Andrew Hsiao. Today's conference call may include forward-looking statements, 00:01:23.637 -- 00:01:28.542 including statements related to the company's research and development and clinical trial 00:01:28.542 -- 00:01:32.786 plans and the tim...